Additionally, GLP-1 RAs also exhibit anti-inflammatory and anti-atherosclerotic effects on the vasculature, which may further improve endothelial function [12, 19]
Obese individuals have a 50% to 100% increased risk of premature death from all causes compared to individuals with a healthy weight
Read more about TB-500 here
Furthermore, recent phase II trial of oncemonthly Maridebart cafraglutide (known as MariTide), a long-acting peptideantibody conjugate that combines GLP-1 receptor agonism and GIPR antagonism, will give us the new opportunity of managing obesity with/without T2D in a monthly-based manner [67]
Ento ajude a divulg-lo compartilhando em suas redes sociais
PIONEER 1: a randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes